Department of Anesthesiology, The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen & Longgang District People's Hospital of Shenzhen, Shenzhen, China.
Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, China.
BMJ Open. 2024 May 2;14(5):e085680. doi: 10.1136/bmjopen-2024-085680.
Transversus abdominis plane (TAP) blocks are commonly used for postoperative analgesia after various abdominal surgeries. There are several different approaches for performing TAP blocks, mainly including posterior, lateral and subcostal approaches. An increasing number of randomised controlled trials (RCTs) have compared the analgesic effects of different TAP block approaches, but the results have not been consistent. This protocol aims to determine the optimal approach of ultrasound-guided TAP blocks for postoperative analgesia after abdominal surgery.
Four databases, including Web of Science, PubMed, EMBASE and the Cochrane Library will be systematically searched to identify RCTs that compared the analgesic effects of different ultrasound-guided TAP block approaches. The search interval will range from the inception of the databases to 30 July 2024. The postoperative opioid consumption over 24 hours will be defined as the primary outcome. The secondary outcomes will include the analgesia duration, postoperative pain scores at rest and during movement at different timepoints and the incidence of adverse effects. All the statistical analyses will be conducted using RevMan V.5.4. The quality of evidence will be evaluated by the Grading of Recommendations Assessment, Development and Evaluation approach.
Ethical approval will not be needed. The results will be submitted to one peer-reviewed journal when completed.
CRD42024510141.
腹横肌平面（TAP）阻滞常用于各种腹部手术后的术后镇痛。有几种不同的方法来进行 TAP 阻滞，主要包括后入路、侧入路和肋下入路。越来越多的随机对照试验（RCT）比较了不同 TAP 阻滞方法的镇痛效果，但结果并不一致。本方案旨在确定超声引导 TAP 阻滞在腹部手术后镇痛中的最佳方法。
将系统检索四个数据库，包括 Web of Science、PubMed、EMBASE 和 Cochrane Library，以确定比较不同超声引导 TAP 阻滞方法镇痛效果的 RCT。检索区间将从数据库建立开始到 2024 年 7 月 30 日。24 小时内术后阿片类药物消耗量将定义为主要结局。次要结局将包括镇痛持续时间、不同时间点静息和运动时的术后疼痛评分以及不良反应的发生率。所有统计分析将使用 RevMan V.5.4 进行。证据质量将通过推荐评估、制定和评估方法进行评估。
不需要伦理批准。完成后，结果将提交给一个同行评审的期刊。
PROSPERO 注册号：CRD42024510141。
